Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CLK1 | P49759 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | STAT3 | P40763 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | PTGES | O14684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10261793 | 0.80 | USP30 (0.39) | CLK1HTR1ANPSR1 | |
| SCHEMBL1400663 | 0.77 | CLK1 (0.40) | ALDH1A1CLK1HPGDGRM5KMT2A | |
| SCHEMBL12987971 | 0.77 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2CLK1HPGDSTAT3 | |
| SCHEMBL2181845 | 0.77 | CLK1 (0.38) | ALDH1A1CLK1HPGDSTAT3GRM5 | |
| SCHEMBL5534329 | 0.76 | MGLL (0.39) | ALDH1A1LMNATP53SMN1; SMN2GRM5 | |
| SCHEMBL3415515 | 0.75 | GRM5 (0.38) | ALDH1A1SMN1; SMN2CLK1HPGDSTAT3 | |
| SCHEMBL69183 | 0.75 | CLK1 (0.36) | ALDH1A1LMNACLK1HPGDSTAT3 | |
| SCHEMBL27854835 | 0.74 | ALDH1A1 (0.37) | ALDH1A1CLK1HPGDGRM5HTR1A | |
| SCHEMBL7656856 | 0.73 | CLK1 (0.38) | ALDH1A1CLK1HPGDSTAT3GRM5 | |
| SCHEMBL6632726 | 0.73 | HTR7 (0.42) | CLK1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249637-A1 | Inhibitors Of Hepatitis C Virus Protease, And Compositions And Treatments Using The Same | COLLINS MICHAEL R | 2007-10-25 | — | — | US | disclosed |
| EP-1805187-A1 | INHIBITORS OF HEPATITIS C VIRUS PROTEASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | Pfizer, Inc. (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006043145-A1 | INHIBITORS OF HEPATITIS C VIRUS PROTEASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249637-A1 | Inhibitors Of Hepatitis C Virus Protease, And Compositions And Treatments Using The Same | SERPINB1, CTSC, CTSV | ALDH1A1 698/4885LMNA 2240/4885TP53 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.